Snowball logo
logo
PARD_logo

Poniard Pharmaceuticals Inc

PARD • PINK
$0.0001$0.00  (0%)
Estimate
EPS
-0.01
Beta
-61.754
About the company
Ticker
PARD
ISIN
US7324494001
Country
United States of America
Sector (GICS)
Healthcare
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Frequently asked questions

What sector does Poniard Pharmaceuticals Inc (PARD) operate in?

Poniard Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Poniard Pharmaceuticals Inc (PARD) current stock price?

As of the latest data, Poniard Pharmaceuticals Inc stock price is $0.00, with a previous close of $0.00.

What is Poniard Pharmaceuticals Inc (PARD) current market capitalization?

Poniard Pharmaceuticals Inc market cap is approximately 149.92.

What is Poniard Pharmaceuticals Inc (PARD) Earnings Per Share (EPS)?

The trailing EPS is -$0.01.

Does Poniard Pharmaceuticals Inc (PARD) pay dividends?

No. Poniard Pharmaceuticals Inc does not pay a dividend.

What is Poniard Pharmaceuticals Inc (PARD) beta (volatility) score?

Poniard Pharmaceuticals Inc has a beta of -61.754, indicating lower volatility than the overall market.